AR056992A1 - Derivados de pirimidina - Google Patents
Derivados de pirimidinaInfo
- Publication number
- AR056992A1 AR056992A1 ARP060101670A ARP060101670A AR056992A1 AR 056992 A1 AR056992 A1 AR 056992A1 AR P060101670 A ARP060101670 A AR P060101670A AR P060101670 A ARP060101670 A AR P060101670A AR 056992 A1 AR056992 A1 AR 056992A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- heterocyclic ring
- group
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Derivados 4-aminocarbonil-pirimidina y su uso como antagonistas del receptor P2Y12 en el tratamiento y/o la prevencion y/o el tratamiento de enfermedades o condiciones vasculares periféricas, viceral-, hepático-, y renal-vasculares, cardiovasculares, y cerebrovasculares asociadas con la agregacion de plaquetas, incluyendo trombosis, en humanos y otros mamíferos. Reivindicacion 1: Un compuesto seleccionado desde el grupo que consiste en los compuestos de formula (1) en la cual: R1 representa fenilo opcionalmente sustituido 1 a 3 veces por substituyentes cada uno independientemente seleccionado desde el grupo que consiste en halogeno, metilo, metoxilo, trifluorometilo y trifluorometoxilo; W representa un enlace, y R2 representa alquilo, haloalquilo, ciano, hidroxialquilo, hidroxialquilo substituido en su cadena alquílica con un grupo fenilo no substituido, alcoxialquilo, heterociclilo, heterociclilalquilo, cicloalquilo, cicloalquilalquilo, arilo, heteroarilo, o uno de los radicales 2 a 5 en los cuales m es 0 y n es 2 o 3, o m es 1 y n es 2; p es 0 y q es 2 o 3, o p es 1 y q es 2, o también p es 2 o 3 y q es 0; Q es -CO- o -CH(ORa)-, siendo Ra H o alquilo, y Q' es -CO-; o W representa -CH2- y R2 representa - NR7R8, -SR9 o -SO2R10; W representa -O- o -S- y R2 representa alquilo, carboxialquilo, alcoxicarbonilalquilo, hidroxialquilo, alcoxialquilo, heterociclilalquilo, cicloalquilo, cicloalquilalquilo, arilo, aralquilo, heteroarilo o heteroarilalquilo; W representa -NR3- y R2 representa H, alquilo, dialquilaminoalquilo, alcoxicarbonilalquilo, carboxialquilo, carboxialquilo substituido en su seccion alquilo con un grupo fenilo, hidroxialquilo, alcoxialquilo, heterociclilo, heterociclilalquilo, cicloalquilo, cicloalquilalquilo, arilo, 2-fenilciclopropilo, aralquilo, difenilalquilo, heteroarilalquilo en donde el heteroarilo es un heteroarilo monocíclico, -COR11 o -SO2R12; W representa -CH=CH- y R2 representa alquilo, hidroxialquilo, alcoxialquilo, alcoxicarbonilo, fenilo o -CO-NR13R14; o W representa -C:::C- y R2 representa H, alquilo, hidroxialquilo o alcoxialquilo; o W representa -CO- y R2 representa alquilo; R3 representa H o alquilo; R7 representa alquilo o arilalquilo; R8 representa alquilo; o R7 y R8 forman, en conjunto con el N que los porta, un anillo heterocíclico de 4 a 7 miembros en el cual los miembros que se necesitan para completar dicho anillo heterocíclico se seleccionan de manera independiente de entre - CH2-, -CH(CH3)-, -CHRy-, -O-, -S-, -CO- y -NRz-, entendiéndose sin embargo que dicho anillo heterocíclico no contiene más que un miembro seleccionado desde el grupo que consiste en -CHRy-, -O-, -S-, -CO- y -NRz-, representando Ry hidroxilo, hidroximetilo, alcoximetilo, alcoxicarbonilo o alcoxilo y representando Rz H, alquilo o alcoxicarbonilo; R9 representa cicloalquilo o arilo; R10 representa alquilo, cicloalquilo o arilo; R11 alquilo, alcoxialquilo, cicloalquilo, cicloalquilalquilo, arilo, heteroarilo monocíclico o aralquilo; R12 representa alquilo o arilo; R13 representa alquilo; R14 representa alquilo; o W representa -NR3- y R2 y R3 forman, en conjunto con el N que los porta, un anillo heterocíclico de 4 a 7 miembros en el cual los miembros que se necesitan para completar dicho anillo heterocíclico se seleccionan de manera independiente de entre -CH2-, -CHRx-, -O-, -S-, -CO- y -NR4- y entendiéndose que dicho anillo heterocíclico no contiene más que un miembro seleccionado desde el grupo que consiste en -CHRx-, -O-, -S-, -CO- y -NR4-, representando Rx hidroxilo, hidroximetilo, alcoximetilo o alcoxilo y R4 representando H o alquilo; o también W representa -NR3- y R2 y R3 forman, en conjunto con el N que los porta, ya sea un anillo imidazolilo, pirazolilo, 1,2,3-triazolilo o 1,2,4-triazolilo, anillo que puede estar substituido con un grupo alquilo, o un anillo 4-oxo-4H-piridin-1-ilo, 4,5-dihidro-pirazol-1-ilo, 2-metil-4,5-dihidro-imidazol-1-ilo o 3- metil-5-oxo-2,5-dihidro-pirazol-1-ilo; cada uno de R5a y R5b representa, de manera independiente, H o metilo; X representa -CO- y R6 representa alquilo, cicloalquilo, alcoxilo, alquiniloxilo, ariloxilo, aralcoxilo, arilo, heteroarilo monocíclico, aralquilo o NR15R16, o X representa -SO2- y R6 representa alquilo; R15 representa alquilo; R16 representa H o alquilo; o R15 y R16 forman, en conjunto con el N que los porta, un anillo heterocíclico de 4 a 7 miembros, en el cual los miembros que se necesitan para completar dicho anillo heterocíclico se seleccionan de manera independiente de entre -CH2-, -O-, -S- y -NRw-, representando Rw H o alquilo, entendiéndose que dicho anillo heterocíclico no contiene más que un miembro del grupo que consiste en -O-, -S- y -NRw-; e Y representa un enlace y Z representa H o arilo substituido por carboxialcoxilo; o Y representa alquileno, alcoxialquileno, fenilalquileno, alcoxifenileno o alcoxifenilalquileno y Z representa H, -OH, -NH2, -COOH, tetrazolilo, -CO-NH2, -COOR17, -NH-CO-R17, -NH-COOR17 o -NH-SO2-R17, representando R17 alquilo; y un enantiomero opticamente puro, una mezcla de enantiomeros, un racemato, un diastereoisomero opticamente puro, una mezcla de diastereoisomeros, un racemato diastereoisomérico, una mezcla de racematos diastereoisoméricos, una meso forma, una sal, un complejo disuelto, o una forma morfologica de los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2005004578 | 2005-04-28 | ||
IB2005053711 | 2005-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR056992A1 true AR056992A1 (es) | 2007-11-07 |
Family
ID=37075078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060101670A AR056992A1 (es) | 2005-04-28 | 2006-04-26 | Derivados de pirimidina |
Country Status (18)
Country | Link |
---|---|
US (1) | US8048881B2 (es) |
EP (1) | EP1893634B1 (es) |
JP (1) | JP4955658B2 (es) |
KR (1) | KR101310016B1 (es) |
CN (1) | CN101166756A (es) |
AR (1) | AR056992A1 (es) |
AT (1) | ATE538130T1 (es) |
AU (1) | AU2006241260A1 (es) |
BR (1) | BRPI0608089A2 (es) |
CA (1) | CA2604967C (es) |
ES (1) | ES2377337T3 (es) |
IL (1) | IL186939A0 (es) |
MX (1) | MX2007013436A (es) |
NO (1) | NO20076094L (es) |
NZ (1) | NZ563584A (es) |
RU (1) | RU2410393C2 (es) |
TW (1) | TW200640877A (es) |
WO (1) | WO2006114774A2 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100210635A1 (en) * | 2006-03-29 | 2010-08-19 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
CL2007002920A1 (es) * | 2006-10-13 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. |
AR063518A1 (es) * | 2006-10-25 | 2009-01-28 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis |
JP5309131B2 (ja) | 2007-04-23 | 2013-10-09 | サノフイ | P2y12アンタゴニストとしてのキノリン−カルボキサミド誘導体 |
DK2225253T3 (da) * | 2007-11-29 | 2012-08-27 | Actelion Pharmaceuticals Ltd | Phosphonsyrederivater og deres anvendelse som p2y12- receptorantagonister |
EP2238127B1 (en) | 2007-12-26 | 2012-08-15 | Sanofi | Pyrazole-carboxamide derivatives as p2y12 antagonists |
JP5504171B2 (ja) * | 2007-12-26 | 2014-05-28 | サノフイ | P2y12アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド |
EP2262766B1 (en) | 2008-02-29 | 2015-11-11 | Evotec AG | Amide compounds, compositions and uses thereof |
AR071653A1 (es) * | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
AR071652A1 (es) * | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
US20110112103A1 (en) * | 2008-04-22 | 2011-05-12 | Daiichi Sankyo Company, Limited | 5-hydroxypyrimidine-4-carboxamide compound |
WO2010033168A2 (en) * | 2008-09-18 | 2010-03-25 | Renovis, Inc. | Amide compounds, compositions and uses thereof |
KR101114503B1 (ko) * | 2008-12-04 | 2012-02-15 | 지에스건설 주식회사 | 부유물 수거장치 |
CA2756542C (en) | 2009-04-08 | 2017-08-22 | Actelion Pharmaceuticals Ltd | 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines |
CN102405220B (zh) * | 2009-04-22 | 2015-05-27 | 埃科特莱茵药品有限公司 | 噻唑衍生物及其作为p2y12受体拮抗剂的用途 |
US8729095B2 (en) | 2009-08-28 | 2014-05-20 | Daiichi Sankyo Company, Limited | 3-(biaryloxy)propionic acid derivatives for prevention and/or treatment of thromboembolic diseases |
WO2013033178A1 (en) | 2011-08-30 | 2013-03-07 | University Of Utah Research Foundation | Methods and compositions for treating nephrogenic diabetes insipidus |
ME02873B (me) | 2011-09-02 | 2018-04-20 | Purdue Pharma Lp | Pirimidini kao blokatori natrijumskog kanala |
UA124073C2 (uk) | 2016-09-22 | 2021-07-14 | Ідорсія Фармасьютікалз Лтд | Кристалічні форми гідрохлориду складного бутилового ефіру 4-((r)-2-{[6-((s)-3-метоксипіролідин-1-іл)-2-фенілпіримідин-4-карбоніл]-аміно}-3-фосфонопропіоніл)-піперазин-1-карбонової кислоти |
EP3595666A1 (en) | 2017-03-15 | 2020-01-22 | Idorsia Pharmaceuticals Ltd | Subcutaneous administration of a p2y12 receptor antagonist |
CN112500354A (zh) * | 2020-12-08 | 2021-03-16 | 烟台凯博医药科技有限公司 | 一种4-氯-6-环丙基嘧啶-5-胺的合成方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5373586A (en) * | 1976-12-09 | 1978-06-30 | Mitsubishi Chem Ind Ltd | New penicillin derivatives |
US6861424B2 (en) * | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
JP4662777B2 (ja) * | 2002-12-11 | 2011-03-30 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 血小板アデノシン二リン酸受容体アンタゴニストとしての2−アミノカルボニルキノリン化合物 |
CL2007002920A1 (es) | 2006-10-13 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. |
AR063518A1 (es) | 2006-10-25 | 2009-01-28 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis |
DK2225253T3 (da) | 2007-11-29 | 2012-08-27 | Actelion Pharmaceuticals Ltd | Phosphonsyrederivater og deres anvendelse som p2y12- receptorantagonister |
AR071653A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2-fenil-4-ciclopropil-pirimidina |
AR071652A1 (es) | 2008-04-11 | 2010-07-07 | Actelion Pharmaceuticals Ltd | Derivados 2- fenil-piridina substituidos |
CA2756542C (en) | 2009-04-08 | 2017-08-22 | Actelion Pharmaceuticals Ltd | 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines |
CN102405220B (zh) | 2009-04-22 | 2015-05-27 | 埃科特莱茵药品有限公司 | 噻唑衍生物及其作为p2y12受体拮抗剂的用途 |
-
2006
- 2006-04-25 TW TW095114722A patent/TW200640877A/zh unknown
- 2006-04-26 AR ARP060101670A patent/AR056992A1/es not_active Application Discontinuation
- 2006-04-27 ES ES06728064T patent/ES2377337T3/es active Active
- 2006-04-27 AU AU2006241260A patent/AU2006241260A1/en not_active Withdrawn
- 2006-04-27 US US11/912,545 patent/US8048881B2/en active Active
- 2006-04-27 RU RU2007143880/04A patent/RU2410393C2/ru not_active IP Right Cessation
- 2006-04-27 WO PCT/IB2006/051318 patent/WO2006114774A2/en active Application Filing
- 2006-04-27 CN CNA2006800143742A patent/CN101166756A/zh active Pending
- 2006-04-27 EP EP06728064A patent/EP1893634B1/en active Active
- 2006-04-27 BR BRPI0608089-8A patent/BRPI0608089A2/pt not_active IP Right Cessation
- 2006-04-27 JP JP2008508400A patent/JP4955658B2/ja active Active
- 2006-04-27 AT AT06728064T patent/ATE538130T1/de active
- 2006-04-27 NZ NZ563584A patent/NZ563584A/en unknown
- 2006-04-27 KR KR1020077026652A patent/KR101310016B1/ko active IP Right Grant
- 2006-04-27 MX MX2007013436A patent/MX2007013436A/es active IP Right Grant
- 2006-04-27 CA CA2604967A patent/CA2604967C/en active Active
-
2007
- 2007-10-25 IL IL186939A patent/IL186939A0/en unknown
- 2007-11-27 NO NO20076094A patent/NO20076094L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1893634A2 (en) | 2008-03-05 |
CA2604967A1 (en) | 2006-11-02 |
US20080194576A1 (en) | 2008-08-14 |
MX2007013436A (es) | 2008-01-16 |
RU2007143880A (ru) | 2009-06-10 |
US8048881B2 (en) | 2011-11-01 |
ATE538130T1 (de) | 2012-01-15 |
NO20076094L (no) | 2008-01-25 |
EP1893634B1 (en) | 2011-12-21 |
NZ563584A (en) | 2011-03-31 |
JP2008539224A (ja) | 2008-11-13 |
AU2006241260A1 (en) | 2006-11-02 |
TW200640877A (en) | 2006-12-01 |
WO2006114774A3 (en) | 2007-02-08 |
JP4955658B2 (ja) | 2012-06-20 |
KR101310016B1 (ko) | 2013-09-30 |
KR20080004608A (ko) | 2008-01-09 |
RU2410393C2 (ru) | 2011-01-27 |
CN101166756A (zh) | 2008-04-23 |
WO2006114774A2 (en) | 2006-11-02 |
CA2604967C (en) | 2014-04-01 |
IL186939A0 (en) | 2008-02-09 |
BRPI0608089A2 (pt) | 2009-11-10 |
ES2377337T3 (es) | 2012-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR056992A1 (es) | Derivados de pirimidina | |
AR063258A1 (es) | Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos. | |
AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
AR075858A1 (es) | Compuestos biciclicos como inhibidores de diacilglicerol aciltransferasa | |
AR067996A1 (es) | Derivados heterociclicos de ciclopropano,composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de afecciones asociadas a receptores de histamina h3, tales como enfermedad de alzheimer y esquizofrenia,entre otros. | |
PE20211871A1 (es) | Agonistas de glp-1r y usos de los mismos | |
PE20060599A1 (es) | DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1 | |
CO6160237A2 (es) | Pirazinonas y pirazinoles sustituidos y composiciones que los comprenden | |
AR048495A1 (es) | Benzoil amino heterociclicos, utiles para el tratamiento de enfermadades intermediadas por glk | |
PE20041078A1 (es) | Derivados heterociclicos inhibidores de la elastasa leucocitica humana (elh) | |
PE20141827A1 (es) | Inhibidores de proteinas quinasas | |
AR052419A1 (es) | Derivados de bencimidazolil n-sustituidos,inhibidores del protooncogen c-kit | |
CO6140060A2 (es) | Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5 | |
ES2452299T3 (es) | Compuestos heterocíclicos fungicidas | |
AR069494A1 (es) | Derivados de acidos fosfonicos | |
PE20061038A1 (es) | Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion | |
ES2567311T3 (es) | 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP | |
AR056888A1 (es) | Derivados de heterociclil imidazol | |
PE20060525A1 (es) | Compuestos heterociclicos como inhibidores de cetp | |
PE20150230A1 (es) | Nuevos diazaespirocicloalcanos y azaespirocicloalcanos | |
AR054369A1 (es) | Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasa | |
PE20120509A1 (es) | Derivados 9,9 difluoro-9h-fluoreno que tiene actividad antiviral | |
AR060562A1 (es) | Compuestos heterociclicos como antagonistas del receptor il-8. procesos de obtencion y composiciones farmaceuticas. | |
AR057770A1 (es) | Inhibidores de la p38-map-quinasa y composicion farmaceutica | |
AR062965A1 (es) | Compuestos moduladores de receptores de glutamatometabotropicos mglur5, composiciones farmaceuticas que los contienen y usos terapeuticos en trastornos gastrointestinales, neurologicos y psiquiatricos agudos y cronicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |